H

Humedix Co Ltd
KOSDAQ:200670

Watchlist Manager
Humedix Co Ltd
KOSDAQ:200670
Watchlist
Price: 36 100 KRW 6.96% Market Closed
Market Cap: 405.4B KRW
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one Humedix Co Ltd stock under the Base Case scenario is hidden KRW. Compared to the current market price of 36 100 KRW, Humedix Co Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Humedix Co Ltd Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

2.3
P/S
P/S
Price to Sales
2.3
vs History
50
vs Industry
43
Median 3Y
2.1
Median 5Y
2.3
Industry
2.4
Forward
1.9
More Details
9.5
P/E
P/E
Price to Earnings
9.5
vs History
92
vs Industry
33
Median 3Y
11.8
Median 5Y
14.1
Industry
20.5
Forward
8
More Details
7.3
P/OCF
P/OCF
Price to OCF
7.3
vs History
77
vs Industry
45
Median 3Y
8.6
Median 5Y
9.5
Industry
15.4
More Details
9.1
P/FCFE
P/FCFE
Price to FCFE
9.1
vs History
66
vs Industry
31
Median 3Y
10.6
Median 5Y
10.1
Industry
22.8
More Details
1.6
P/B
P/B
Price to Book Value
1.6
vs History
73
vs Industry
38
Median 3Y
1.7
Median 5Y
1.7
Industry
1.9
More Details
1.6
EV/S
EV/S
Enterprise Value to Sales
1.6
vs History
74
vs Industry
49
Median 3Y
1.6
Median 5Y
1.9
Industry
2.5
Forward
1.4
More Details
3.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.5
vs History
79
vs Industry
43
Median 3Y
3.9
Median 5Y
4.4
Industry
4.9
More Details
4.8
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
4.8
vs History
82
vs Industry
43
Median 3Y
5.6
Median 5Y
6.3
Industry
12.4
Forward
4.2
More Details
6.1
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
6.1
vs History
90
vs Industry
40
Median 3Y
7.6
Median 5Y
9.6
Industry
15.5
Forward
4.9
More Details
5.2
EV/OCF
EV/OCF
Enterprise Value to OCF
5.2
vs History
80
vs Industry
48
Median 3Y
6.4
Median 5Y
7.8
Industry
14
More Details
6.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
6.3
vs History
71
vs Industry
35
Median 3Y
7.8
Median 5Y
9.5
Industry
17.9
More Details
1.9
EV/IC
EV/IC
Enterprise Value to IC
1.9
vs History
41
vs Industry
31
Median 3Y
1.7
Median 5Y
1.6
Industry
1.8
More Details

Multiples Across Competitors

Competitors Multiples
Humedix Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
Humedix Co Ltd
KOSDAQ:200670
372.3B KRW 2.3 9.5 4.8 6.1
US
Eli Lilly and Co
NYSE:LLY
669.1B USD 15 64.1 36.9 40.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
356B USD 4 25.3 11.9 15.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK 6.3 18 11.9 13.6
CH
Roche Holding AG
SIX:ROG
193.7B CHF 3.3 16.8 9.5 11.3
CH
Novartis AG
SIX:NOVN
171.4B CHF 3.9 16.8 10.2 13.1
UK
AstraZeneca PLC
LSE:AZN
155.3B GBP 3.7 28.3 125.4 191.5
US
Merck & Co Inc
NYSE:MRK
195.2B USD 3 11.4 7.8 9.2
IE
Endo International PLC
LSE:0Y5F
162.4B USD 70 -55.5 259.5 650.8
US
Pfizer Inc
NYSE:PFE
122.1B USD 1.9 15.2 7.6 10.9
P/E Multiple
Earnings Growth PEG
KR
H
Humedix Co Ltd
KOSDAQ:200670
Average P/E: 22.8
9.5
23%
0.4
US
Eli Lilly and Co
NYSE:LLY
64.1
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
25.3
26%
1
DK
Novo Nordisk A/S
CSE:NOVO B
18
19%
0.9
CH
Roche Holding AG
SIX:ROG
16.8
16%
1.1
CH
Novartis AG
SIX:NOVN
16.8
16%
1
UK
AstraZeneca PLC
LSE:AZN
28.3
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.4
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -55.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
15.2
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KR
H
Humedix Co Ltd
KOSDAQ:200670
Average EV/EBITDA: 393.8
4.8
19%
0.3
US
Eli Lilly and Co
NYSE:LLY
36.9
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
11.9
7%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11.9
15%
0.8
CH
Roche Holding AG
SIX:ROG
9.5
8%
1.2
CH
Novartis AG
SIX:NOVN
10.2
5%
2
UK
AstraZeneca PLC
LSE:AZN
125.4
9%
13.9
US
Merck & Co Inc
NYSE:MRK
7.8
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
259.5
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
3%
2.5
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
KR
H
Humedix Co Ltd
KOSDAQ:200670
Average EV/EBIT: 1 696.8
6.1
25%
0.2
US
Eli Lilly and Co
NYSE:LLY
40.7
33%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
15.6
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
13.6
16%
0.8
CH
Roche Holding AG
SIX:ROG
11.3
9%
1.3
CH
Novartis AG
SIX:NOVN
13.1
8%
1.6
UK
AstraZeneca PLC
LSE:AZN
191.5
21%
9.1
US
Merck & Co Inc
NYSE:MRK
9.2
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
650.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.9
10%
1.1

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 245,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.